CRISPR Therapeutics AG cotiza a 50.12 USD y tiene una capitalización bursátil de $4.8B. En los últimos 12 meses ha facturado $13M con un margen de flujo de caja libre del -9855.5%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process …
| Métrica | CRSP | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -18933.7% | -38.6% | -18895.0% |
| Net Margin | -16569.8% | -33.6% | -16536.2% |
| FCF Margin | -9855.5% | -13.9% | -9841.6% |
| ROE | -30.3% | -40.4% | +10.1% |
| ROA | -25.7% | -32.0% | +6.3% |
| Current Ratio | 13.32 | 2.84 | +10.48 |
| Debt / Equity | — | 0.28 | — |